Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow up of TBI-1301
jRCT1043210160Active, not recruiting
- Sponsor
- Takara Bio Inc.
- Start
- Jun 2015
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-NY-ESO-1 TCR-T in Nonhematologic neoplasms, sponsored by Takara Bio Inc. Primary endpoints: Detection of replication-competent retrovirus and Detection of cell clonality. Started Jun 2015; status: active, not recruiting.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1043210160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1043210160.